to Oslo Medtech
Register here to subscribe to our newsletter!
Oslo Medtech latest newsletter (May 2013)
Interested in previous newsletters? Click here
Generating innovation. For better living and health.
PCI Biotech wins the Innovation Award of one million NOK. In addition, the company won the People's price of 100.000 NOK. The money will go to further research on the company's treatment for cancer. PCI Biotech is working intensely to deliver a new treatment against cancer. In cooperation with the Norwegian Radium Hospital has PCI Biotech developed and patented a photosensitive drug that allows the local treatment of cancer tumors. The cure may enhance the effects of chemotheraphy up to a hundred times.
Read more at InnoDesign
PCI Biotech Holding ASA
PCI Biotech is an oncology-focused company developing combination products for localised cancer treatment. The products are based on PCI Biotech’s patented drug delivery technology, photochemical internalization (PCI), which can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells. The lead product, PC-A11, combines the proprietary photosensitiser Amphinex® with the well established cytotoxic agent bleomycin.